Amgen to Host Oncology Webcast October 24
The Thousand Oaks-based company will present clinical data and discuss its oncology portfolio during the ESMO Congress 2026.
Updated on Oct. 20, 2026 in Cancer
Amgen will host an investor webcast on October 24, 2026, at 11:30 a.m. PT to discuss its oncology portfolio and clinical data presented at the ESMO Congress 2026. The biotech firm plans to broadcast the session live via its investor relations website.
Why it matters
This event serves as a platform for Amgen to detail the latest findings from its cancer research pipeline to investors and the broader medical community. Sharing this clinical data provides insights into the company's long-term research trajectory and therapeutic progress.
Amgen, a component of both the Dow Jones Industrial Average and the Nasdaq-100 Index, will provide access to the webcast for at least 30 days following the event.
The players
Amgen
Headquartered in Thousand Oaks, California, this biotechnology company is a member of the Dow Jones Industrial Average and the Nasdaq-100 Index.
Murdo Gordon
He is an executive at Amgen who will participate in the scheduled investor webcast to discuss the company's clinical data.
Jean-Charles Soria
He is an executive at Amgen who will participate in the scheduled investor webcast to discuss the company's oncology portfolio.
The details
Executives Murdo Gordon and Jean-Charles Soria will lead the discussion regarding the company's oncology developments during the global congress. Participants can access the broadcast through the investor relations calendar on the Amgen website.
Timeline
October 24, 2026, at 11:30 a.m. PT: Amgen hosts investor webcast at ESMO Congress.
For at least 30 days after October 24, 2026: The company will archive the webcast for replay.
The Big Picture
This announcement follows the pattern set by global pharmaceutical companies that synchronize critical clinical updates with major medical forums like the ESMO Congress 2026. Such events are standard practice for communicating significant therapeutic breakthroughs to the financial and medical sectors.
The presentation of clinical data during this webcast provides a look at the future treatment options currently in development for oncology patients. While the event is geared toward investors, the reported results may eventually inform potential advancements in medical care and therapeutic availability.
The takeaway
Investors and those interested in the biotech sector should check the Amgen investor relations portal for archive access following the live presentation. This event highlights the company's focus on maintaining transparency regarding clinical data during major medical industry gatherings.
Further reading
For more information on the industry landscape, see the Cancer section.
